Clinical Trial Update: Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating imatinib mesylate in combination with daunorubicin and cytarabine for relapsed acute myeloid leukemia. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Cerubidine (Daunorubicin hydrochloride)
• Gleevec (Imatinib)

Snippet

Sponsor: The Cleveland Clinic | Conditions: Leukemia | Phase 1 | Status: COMPLETED